Daiichi Sankyo Co., Ltd. (4568) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daiichi Sankyo Co., Ltd. (4568:JPX), powered by AI.

Current Price
¥2,546
P/E Ratio
16.3
Market Cap
4.8T
Sector
Healthcare
What is the Daiichi Sankyo Co., Ltd. stock price forecast?

Daiichi Sankyo Co., Ltd. is currently trading at ¥2,546. View real-time AI analysis on Alpha Lenz.

What is Daiichi Sankyo Co., Ltd. insider trading activity?

View the latest insider trading data for Daiichi Sankyo Co., Ltd. on Alpha Lenz.

What is Daiichi Sankyo Co., Ltd.'s P/E ratio?

Daiichi Sankyo Co., Ltd.'s P/E ratio is 16.3.

Daiichi Sankyo Co., Ltd.

JPX · 4568
¥2,546+46(+1.82%)Market closedJPX regular session 09:00–15:00 JST
Ask about Daiichi Sankyo Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Daiichi Sankyo Co., Ltd. trades at a P/E of 16.3 (fair value) with strong ROE of 17.9%. 3Y revenue CAGR of 21.8% highlights clear growth momentum.

Ask for details

Company Overview

Daiichi Sankyo Co., Ltd. is a prominent pharmaceutical company based in Japan, specializing in the research, development, and manufacturing of pharmaceutical products. The company's primary focus is on developing innovative treatments across several critical therapeutic areas such as oncology, cardiovascular diseases, and rare genetic conditions. Notable for its robust pipeline of drugs, Daiichi Sankyo aims to leverage cutting-edge science in antibody-drug conjugates and other novel drug delivery systems to provide advanced treatments for unmet medical needs. As a key player in the global pharmaceutical industry, Daiichi Sankyo impacts multiple sectors, including healthcare services and biotechnology. Its strategic collaborations with other leading global pharmaceutical companies further enhance its growth prospects and innovation capabilities. Headquartered in Tokyo, Japan, and with a broad international footprint, Daiichi Sankyo holds significant market significance. It plays a vital role in advancing global healthcare solutions, ensuring a pipeline of emerging therapies can address future challenges in medical treatment.

CEOMr. Hiroyuki Okuzawa
SectorHealthcare
IndustryDrug Manufacturers - General
Employees19,765

Company Statistics

FY 2025

Profile

¥4,828,127,572,386Market Cap
¥1,886,256,000,000Revenue
0.00Shares Out
19,765Employees

Margins

77.96%Gross
23.12%EBITDA
17.60%Operating
18.85%Pre-Tax
15.68%Net

Valuation

16.32P/E
2.97P/B
2.56EV/Sales
9.84EV/EBITDA
-36.02P/FCF

Growth (CAGR)

21.76%Rev 3Yr
13.95%Rev 5Yr
65.65%Op Inc 3Yr
19.05%Op Inc 5Yr
64.06%Net Inc 3Yr
18.06%Net Inc 5Yr

Returns

8.55%ROA
17.86%ROE
10.63%ROIC

Financial Health

¥639,838,000,000Cash & Cash Equivalents
¥1,192,865,000,000Net Debt
112.89%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Daiichi Sankyo Co., Ltd. (ticker: 4568) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 19,765 employees. Market cap is $4.8T.

The current price is 2,546 with a P/E ratio of 16.32x and P/B of 2.97x.

ROE is 17.86% and operating margin is 17.60%. Annual revenue is $1.9T.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Daiichi Sankyo Co., Ltd. (4568) Stock Forecast 2026 ¥2,546 — Price, Financials & Analyst Targets | Alpha Lenz